Amaze: a double-blind, multicentre randomised controlled trial to investigate the clinical effectiveness and cost-effectiveness of adding an ablation device-based maze procedure as an adjunct to routine cardiac surgery for patients with pre-existing atrial fibrillation

Linda Sharples,<sup>1</sup>\* Colin Everett,<sup>2</sup> Jeshika Singh,<sup>3</sup> Christine Mills,<sup>4</sup> Tom Spyt,<sup>5</sup> Yasir Abu-Omar,<sup>6</sup> Simon Fynn,<sup>6</sup> Benjamin Thorpe,<sup>2</sup> Victoria Stoneman,<sup>4</sup> Hester Goddard,<sup>4</sup> Julia Fox-Rushby<sup>7</sup> and Samer Nashef<sup>6</sup>

 <sup>1</sup>Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK
<sup>2</sup>Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
<sup>3</sup>Health Economics Research Group (HERG), Brunel University London, London, UK
<sup>4</sup>Papworth Trials Unit Collaboration, Papworth Hospital, Cambridge, UK
<sup>5</sup>Department of Cardiac Surgery, Glenfield Hospital, Leicester, UK
<sup>6</sup>Department of Cardiology and Department of Cardiothoracic Surgery, Papworth Hospital, Cambridge, UK
<sup>7</sup>Department of Deputation Science, King's College London, London, UK

<sup>7</sup>Department of Population Science, King's College London, London, UK

\*Corresponding author Linda.Sharples@lshtm.ac.uk

**Declared competing interests of authors:** Samer Nashef received personal expenses from AtriCure, Inc. (Amsterdam, the Netherlands) for contributing to educational courses for surgeons interested in learning the maze procedure, independently of this study. AtriCure, Inc. is one of several manufacturers of atrial fibrillation ablation devices, the technology of which was used in atrial fibrillation surgery in this study.

Published April 2018 DOI: 10.3310/hta22190

# **Plain English summary**

Amaze: a double-blind, multicentre randomised controlled trial Health Technology Assessment 2018; Vol. 22: No. 19 DOI: 10.3310/hta22190

NIHR Journals Library www.journalslibrary.nihr.ac.uk

## **Plain English summary**

rregular heartbeat is common, and the most common type is atrial fibrillation (AF). The heart has four chambers: two ventricles that propel blood from the heart and two atria that receive blood. In AF, the chambers of the heart lose their pumping action and the heart becomes less efficient. Blood can settle in the atria and form clots. These can detach and cause strokes, so AF patients are given blood-thinning drugs to reduce this risk. These drugs can increase the risk of bleeding. The maze procedure is an operation designed to stop AF and make the heart beat regularly again.

Many patients who need major heart surgery also have AF. The Amaze trial was designed to find out whether or not adding a maze procedure to heart operations is useful in making the heartbeat regular again, if it improves long-term survival and quality of life (QoL) and whether or not any benefits are worth the extra costs.

Between 25 February 2009 and 6 March 2014, 352 patients in 11 hospitals were recruited and randomly put into one of two treatment groups: (1) maze and planned heart surgery or (2) planned surgery alone. The results showed that patients in the maze group were more likely to have a normal, regular heartbeat afterwards; however, there were no differences in survival or QoL at 2 years. In addition, many maze patients who recovered a regular heartbeat did well in terms of the heart's pumping action, suggesting that longer follow-up may show better QoL and survival in these patients.

© Queen's Printer and Controller of HMSO 2018. This work was produced by Sharples et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

## **Health Technology Assessment**

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.236

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

#### Criteria for inclusion in the Health Technology Assessment journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

#### **HTA programme**

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

#### This report

The research reported in this issue of the journal was funded by the HTA programme as project number 07/01/34. The contractual start date was in September 2008. The draft report began editorial review in January 2017 and was accepted for publication in August 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2018. This work was produced by Sharples *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

## Health Technology Assessment Editor-in-Chief

**Professor Hywel Williams** Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

### **NIHR Journals Library Editor-in-Chief**

Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

### **NIHR Journals Library Editors**

**Professor Ken Stein** Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andrée Le May Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

**Professor Matthias Beck** Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson Director of the NIHR Dissemination Centre, University of Southampton, UK

Ms Tara Lamont Scientific Advisor, NETSCC, UK

**Dr Catriona McDaid** Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Professor of Wellbeing Research, University of Winchester, UK

**Professor John Norrie** Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood** Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk